Podcasts about Moderna

Je spoluiniciátorem ambientního a elektroakustického alba současných českých skladatelek a skladatelů Moderna vydaného Českým rozhlasem Vltava. Představuje průřez současnými hudebními díly na pomezí moderní klasiky, ambientu, neoklasiky i filmové hudby. „Propojování je pro mě ta nejpřirozenější cesta. Baví mě vyprávět příběhy, spojovat světy, propojovat lidi a tvořit,“ vysvětluje ve Vizitce. Všechny díly podcastu Vizitka můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Saša Michailidis se ptá hostů, zda jsou knihy spisovatele a filozofa Umberta Eca otevřené skutečně všem čtenářům. V Radioseriálu Vltavy si můžete poslechnout Foucaultovo kyvadlo. Umění v pražském metru. Špálovy Kytky v Museu Kampa a popularita české výtvarné moderny. Web Umělecké památky jako cesta k poznávání architektury kolem nás. Všechny díly podcastu Akcent můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

In this episode, conceptual artist Ahmet Öğüt travels by train through Ottoman Turkey, the former Yugoslavia and Western Balkans, to the London Underground today, navigating histories and contemporary expressions of solidarity via the 2025 programme, Revolutionary Roads. Destination: Comradeship.Revolutionary Roads. Destination: Comradeship was organised by the Moderna galerija in Ljubljana, the Museum of African Art in Belgrade, and the Museum of Contemporary Art of Montenegro in Podgorica in August 2025.Ahmet Öğüt: Saved by the Whale's Tail, Saved by Art is at Stratford Station in London until December 2026, commissioned by Art on the Underground and New Contemporaries.Museum Yet to Be is at the Museum of Contemporary Art of Montenegro in Pogdorica until 15 March 2026.Translated into Socialism was at the Moderna galerija in Ljubljana until 8 February 2026.The East Remains Possible is at the Museum of Contemporary Art in Skopje (MoCA – Skopje) until March 29, 2026.For more from Art on the Underground, listen to contemporary artist Barby Asante on her collective choral performance, Declaration of Independence (2023), at Stratford Station in London: pod.link/1533637675/episode/aa2803b68933ab974ca584cf6a18479cAnd on migrations between Turkey and France, hear Nil Yalter, awardee of the Golden Lion for Lifetime Achievement at the Venice Biennale in 2024, at Ab-Anbar Galleryduring London Gallery Weekend 2023, with Exile is a Hard Job (1974-Now): pod.link/1533637675/episode/36b8c7d8d613b78262e54e38ac62e70fPRODUCER: Jelena Sofronijevic.Follow EMPIRE LINES on Twitter: twitter.com/jelsofron/status/1306563558063271936And Instagram: instagram.com/empirelinespodcastSupport EMPIRE LINES on Patreon: patreon.com/empirelines

Saša Michailidis se ptá šéfkurátora pražského Musea Kampa Jana Skřivánka a ředitele Galerie výtvarného umění v Chebu Marcela Fišera. Museum Kampa připravilo výstavu Václav Špála: Kytky. Právě on patří k představitelům tuzemské výtvarné moderny, kterou datujeme od konce 19. do zhruba poloviny 20. století. Jak s díly malířů tohoto období pracují kurátoři?Všechny díly podcastu Akcent můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

As terras-raras estão no centro da transição energética, da inovação tecnológica e da soberania digital, mas seguem desconhecidas para a maior parte das pessoas. São 17 elementos químicos essenciais para tudo o que move o mundo contemporâneo: celulares, carros elétricos, turbina eólicas, servidores que armazenam dados bancários e até tecnologias de biometria usadas na prevenção de fraudes. Embora não sejam tão “raras”, sua extração e, principalmente, o refino são complexos e concentrados em poucos países, o que cria riscos estratégicos para economias inteiras.​No novo episódio do Febraban Podcast, mergulhamos no universo das terras-raras para entender por que esses minerais se tornaram tão críticos, e por que o Brasil, dono de quase um quarto das reservas mundiais, ainda não consegue transformar esse potencial em desenvolvimento tecnológico e industrial.​​Neste episódio, você vai descobrir:​O que são terras-raras e por que são insumos críticos na atualidade​Como esses 17 elementos entram em energia limpa, semicondutores e defesa​Por que o refino das terras-raras é um grande gargalo​Como a China domina a cadeia de terras-raras​Os riscos geopolíticos da concentração do mercado de terras-raras​Impacto no mercado financeiro/bancos: chips, fibras óticas, satélites e infraestrutura digital​O potencial brasileiro de terras-raras, com projetos em Goiás, Minas Gerais e Amazônia​Por que o país precisa de política industrial, pesquisa e transferência de tecnologia direcionada para terras-raras​O poder de barganha do Brasil na disputa global por minerais críticos​​Com Paulo Feldmann (FEA-USP) e Francisco Valdir Silveira (Serviço Geológico do Brasil), sob condução de Mona Dorf (Febraban).​​Acompanhe o Febraban Podcast para novos episódios toda quinta-feira.FICHA TÉCNICA:Apresentadora e Editoria-chefe: Mona DorfSupervisão Geral e Co-apresentação: Carlos Cidra e Májory MarcelinoSupervisão e Produção: Bianca Braga, Julia Alcassa e Leandro LemellaRoteiro, edição e produção: Rachel Cardoso, Patrícia Travassos e Clovis TravassosEdição de vídeo: Leonardo Reali e Kris ArrudaVideomaker backstage: Kris ArrudaGravação: Supernova Cinematográfica

McKay reveals why the most critical factor for success in business and life isn't the product, price, or timing, but the power of a compelling story. He demonstrates that the "best story wins" by reframing value, creating emotional connection, and motivating action in ways that data and features alone cannot.Drawing on case studies from disruptive brands like Canva, Duolingo, and Moderna, McKay shows how storytelling can redefine entire industries. He breaks down powerful communication frameworks, including Simon Sinek's "Golden Circle," Donald Miller's "StoryBrand," and Barbara Minto's "Pyramid Principle," to provide a clear roadmap for crafting impactful narratives. By positioning the customer as the hero and the business as the guide, he illustrates how to move beyond product features to address core human motivations and frustrations. Ultimately, this episode equips listeners with the tools to craft irresistible stories that capture attention, build loyalty, and drive results.Main Themes:Why the best story always wins in businessThe StoryBrand Framework: Positioning the customer as the heroSimon Sinek's Golden Circle: Starting with "Why"The Pyramid Principle: Leading with the answer firstCase studies in storytelling: Canva, Duolingo, Apple, and PatagoniaUsing "anticipation hooks" to engage listenersTapping into the brain's "narrative network" to create emotional connectionHow fictional stories dramatically increased the value of simple productsReframing complex technology (Moderna's mRNA) into a simple, empowering narrativeShifting from a product-focused to a story-focused sales approachTop 10 Quotes:"The best story wins.""A story is a piece of information wrapped in emotion.""People don't buy what you do; they buy why you do it.""Your customer is the hero. You are not, nor is your product. You are the guide.""When you start with ‘why', you attract believers, not just buyers.""Stories put the other person in receptive mode.""Instead of injecting a vaccine, we teach your body how to solve the problem itself.""Clarity beats suspense or confusion every time.""Beliefs drive actions, both positive and negative."Show Links:Open Your Eyes with McKay Christensen

A decocção é uma das técnicas mais tradicionais, e também mais trabalhosas, da história da produção de cerveja. Mas será que ainda faz sentido aplicar esse processo completo hoje? E existe um caminho mais simples para chegar perto do mesmo resultado sensorial?Neste episódio do Brassagem Forte, Henrique Boaventura recebe Jamal Awadallak para um mergulho técnico na decocção moderna e nas abordagens modernas que buscam preservar caráter maltado, profundidade de sabor e eficiência de conversão sem transformar a brassagem em uma maratona de horas.Ao longo da conversa, você vai entender o que realmente acontece no mosto durante a decocção, desde da gelatinização do amido às mudanças no perfil de aminoácidos, FAN e fermentação, além das diferenças entre as tradições alemã e tcheca, os impactos sensoriais das decocções simples, dupla e tripla, e como processos como Schmitz e a própria decocção reversa oferecem atalhos técnicos consistentes.Também discutimos transferência de calor, formação de melanoidinas, uso estratégico de malte melanoidin e os limites reais entre fidelidade histórica, praticidade moderna e resultado no copo. Um episódio essencial para quem quer produzir lagers mais complexas sem necessariamente perder o dia inteiro na brassagem.

Per approfondire gli argomenti della puntata: Altre pillole dedicate all'Età Moderna : https://www.youtube.com/watch?v=04jMzzw0qK4&list=PLpMrMjMIcOkkxE3VRfoFOph9H6S2v2Njr&ab_channel=LaBibliotecadiAlessandria Learn more about your ad choices. Visit megaphone.fm/adchoices

Broadcast from KSQD, Santa Cruz on 3-05-2026: Dr. Dawn demonstrates how to critically read a science paper using a widely-publicized study claiming adolescent cannabis use causes psychotic, bipolar, and anxiety disorders. She identifies multiple methodological problems: only 5.7% of Kaiser adolescents admitted cannabis use versus 11.2% in anonymous national surveys, suggesting massive underreporting; the study conflates any use with heavy use; and with 463,000 participants, trivially small differences become statistically significant but clinically meaningless. She proposes reverse causation—that prodromal schizophrenia symptoms may drive teens to self-medicate with cannabis rather than cannabis causing psychosis. The study also included "disruptive behavior disorder" diagnoses that lack rigorous criteria, and she notes diagnostic codes are sometimes chosen for insurance reimbursement rather than accuracy. While acknowledging high-dose THC before age 16 may affect brain development, she concludes the headlines claiming causation are not supported by the actual findings. Dr. Dawn discusses how aquaculture—now producing 60% of fish consumed globally—has become a breeding ground for antibiotic-resistant pathogens. More antibiotics per kilogram are used in fish farming than in any other animal agriculture, with drugs dissolving into water and sediment where bacteria develop resistance. One study found antibiotic-resistant bacteria in over 80% of shrimp species tested across multiple countries. Through horizontal gene transfer, these resistance genes spread to human pathogens—a 1991 Latin American cholera outbreak affecting nearly a million people may have acquired drug resistance from Ecuadorian shrimp farms. Dr. Dawn reports that the FDA rejected Moderna's mRNA flu vaccine application without even reviewing it, despite trials of 41,000 people showing it was 27% more effective at preventing illness and 29% more effective at preventing hospitalization than existing vaccines. She attributes this to politicized anti-mRNA bias lacking scientific basis, noting that venture capital investors like Blackstone (who invested $750 million) will now avoid vaccine development, effectively handing this critical technology to other countries. Dr. Dawn describes the "wellness industrial complex"—pharmaceuticals, tech, testing companies, and health influencers creating content that pathologizes normal behaviors. YouTube health videos have amassed 200 billion views, and 30% of British respondents now get medical advice from AI chatbots. She cites a 400% increase in British adults seeking ADHD diagnoses, noting that analysis of top TikTok ADHD videos found less than 50% accurately reflected actual symptoms. Many influencers receive undisclosed payments to mention products, and the U.S. and New Zealand are the only countries allowing direct-to-consumer drug advertising. A caller asks about navigating Medicare after their Advantage plan was terminated with no local providers accepting remaining plans. Dr. Dawn explains that Medicare Advantage companies took extra government payments meant for wellness programs but didn't build them, and are now exiting markets as costs rise. She recommends contacting Gray Bears or AARP for free Medicare navigation assistance and suggests exploring regular Medicare with a secondary plan or direct-pay practices. /li>

Even in a world on fire with yet another big war there are glimmers of light such as the upcoming Festival of Humanism in Bournemouth in June. In TWISH we hear about some of the most common myths about Michelangelo, and then we take a look at the news:EU: Vaccine update: EMA recommends approval of Moderna's combined flu/covid vaccine and more good news regarding HPV vaccinationGERMANY: Fake vaccinations currently under investigationUK / WALES: Follow-up: Assisted dying in the UK and WalesINTERNATIONAL: Lessons from the latest Freedom of Thought ReportThe Really Wrong Award goes to unnecessary supplements for middle-aged men (they don't do much for other people either…)Enjoy!https://theesp.eu/podcast_archive/theesp-ep-521.htmlSegments:0:00:27 Intro0:00:50 Greetings0:05:51 TWISH0:19:51 News0:45:46 Really Wrong0:50:03 Who's Quacking?0:53:44 Quote0:55:11 Outro0:56:34 Outtakes Hosted on Acast. See acast.com/privacy for more information.

On this week's episode, Mike Yee, Eric Schmidt, Matt Gline, and Yaron Werber kick off with a discussion on the sector's resilience amid market volatility, highlighting positive capital markets developments. The fourth quarter of 2025 saw approximately $10 billion in follow-on financing, with the first quarter of 2026 approaching about a $2.5 billion IPO run rate, which would be the highest single quarter in the past few years. The co-hosts express cautious optimism, notingthat after a long period where companies were struggling to capitalize themselves, the overall mood has improved. The discussion then shifts to the big news from this week and intellectual property dynamics including the $2.25B Roivant/Moderna settlement and its impacts on Moderna's cash position, alongside IP implications for mRNA/LNP platforms. Regulatory updates are mentioned through UniQure's rejection and FDA decision-making, emphasizing the complexity of FDA reviews. The group also explores the GLP-1 obesity market potential and its impact on consumer sectors, particularly with the emergence of oral GLP-1 therapies; payer dynamics are also discussed. Next, the co-hosts discuss financial guidance and “sandbagging” using the Harrow case as an example in transparency in financial guidance and its impact on investor expectations. The episode concludes with the group highlighting Miami as an emerging hub for biotech and finance conferences, offering efficient scheduling for deal-making. *This episode aired on March 6, 2026. 

We've had many conversations on Raise the Line about the challenges of health communication in today's world of information overload, but none of our guests have the kind of expertise Dr. Tesfa Alexander has acquired in a career that has taken him from Madison Avenue to the halls of government and academia. From guiding tobacco education research at the FDA to leading public health initiatives at MITRE, Dr. Alexander has developed a deep understanding of the science and strategy behind effective health communication. “Successful campaigns keep the long game in mind where you want to develop a lasting relationship with your target audience,” he tells host Lindsey Smith. That relationship needs to be built on understanding culture, beliefs, priorities and daily realities, and only then can you develop messaging that will resonate, he explains. Dr. Alexander also believes these relationships can be leveraged to help people sort out facts from misleading or inaccurate claims. “I strongly recommend shifting our focus from combating misinformation head on, and instead working with the communities who we are seeking to serve.” This fascinating look at communication science also covers: How stories drive belief; The importance of working with community partners who are trusted messengers;  The power of audience segmentation. Tune in as Dr. Alexander unpacks what it takes to influence beliefs, and ultimately behaviors, in an era defined by misinformation and institutional mistrust. Mentioned in this episode:Lerner Center for Public Health Advocacy If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that highlight the intricate interplay of scientific innovation, regulatory dynamics, and strategic maneuvers shaping the industry.Starting with Moderna, the company has reached a pivotal resolution in a long-standing patent dispute involving its mRNA-based COVID-19 vaccine, Spikevax. This settlement involves a hefty $950 million payout to Genevant Sciences and Arbutus Biopharma, resolving claims of patent infringements. This agreement underscores the complex nature of intellectual property in the rapidly evolving mRNA landscape. Securing patent rights is crucial as new vaccines and therapies are developed, and this resolution not only clears a legal hurdle for Moderna but also exemplifies the industry trend towards resolving such disputes to foster continuous innovation.Sanofi has embarked on a significant strategic move by entering a $1.53 billion global licensing deal with Sino Biopharmaceutical. This agreement secures rights to a first-in-class JAK/ROCK inhibitor, which shows promise in treating hematological and immunological conditions. Such collaborations reflect the increasing focus on innovative therapies that target complex biological pathways, highlighting how companies are seeking unique assets to bolster their competitive edge.Regulatory scrutiny continues to be a formidable theme in the industry. The FDA has intensified its oversight on compounded GLP-1 drugs, issuing 30 warning letters to telehealth companies marketing unauthorized versions. This action highlights the agency's commitment to ensuring drug safety and efficacy while emphasizing the challenges companies face in navigating regulatory landscapes for compounded medications. Additionally, Novo Nordisk has been cautioned by the FDA regarding advertising practices for GLP-1 receptor agonists, illustrating the ongoing regulatory focus on pharmaceutical marketing strategies and compliance standards.Meanwhile, Bayer is experiencing a period of resilience in its pharmaceutical division, driven largely by its cancer drug Nubeqa and cardiovascular agent Kerendia. Despite these successes, Bayer faces challenges as revenues from older drugs like Xarelto and Eylea decline. This scenario reflects a broader industry challenge where companies must innovate while managing mature product lines facing generic competition.Teva Pharmaceuticals is making strategic strides by securing a $400 million deal with Blackstone to develop an anti-TL1A antibody for inflammatory bowel disease (IBD), in partnership with Sanofi. This investment highlights continued interest in autoimmune and inflammatory conditions as lucrative targets for novel therapies. Financial partnerships like Teva's substantial agreement with Blackstone illustrate how such collaborations can support sustained R&D efforts in chronic disease management.Technological integration into healthcare is expanding rapidly, with Nvidia collaborating with Droplet Biosciences to explore AI applications in medtech and cancer research. These partnerships illustrate an industry shift towards leveraging artificial intelligence to enhance diagnostic capabilities and accelerate research efforts. Moreover, collaborations leveraging AI/ML technologies across drug discovery pipelines are gaining traction; Earendil Labs partnering with WuXi XDC exemplifies this trend alongside Merck & Co.'s multi-year AI oncology data deal with Tempus—enhancing precision medicine capabilities while expediting therapeutic discoveries.In terms of funding new therapeutic areas, ARPA-H has announced a $158 million initiative aimed at developing medicines targeting the lymphatic system. This marks an exploration into less charted territories within physiological research that could yield transforSupport the show

In this week's episode of Medicine: The Truth, hosts Jeremy Corr and Dr. Robert Pearl unpack a wide range of developments shaping healthcare in America today, including the TrumpRx drug discount program. From new legislation affecting telehealth and pharmacy benefit managers (PBMs) to the rapid spread of measles and growing public concern about vaccine policy, this month's discussion highlights the policy decisions and scientific debates influencing medicine right now. The episode opens with the latest federal legislation passed to avert a government shutdown. While healthcare was not the central focus of this particular political battle, the bill contains several provisions that affect medical practice. These include extensions for telehealth coverage and hospital-at-home programs, reforms targeting PBM transparency and new requirements designed to address “ghost networks” in Medicare Advantage provider directories. Dr. Pearl explains that while these provisions represent incremental progress, they are unlikely to solve the larger problems driving healthcare costs and access challenges in the United States. Here are the other major storylines from episode 104: Healthcare costs remain nation's top concern: A new KFF poll finds that healthcare expenses rank above food, housing and utilities as the economic issue Americans worry about most. Prior authorization frustrations grow: Many patients report delays or denials of care due to insurance requirements, highlighting persistent tension between insurers, physicians and patients. Drug pricing debates continue: Pearl examines a new prescription drug website initiative and explains why it may have limited impact compared with broader policy proposals such as “most favored nation” pricing. Telehealth's uncertain future: Although the latest legislation extends certain pandemic-era flexibilities, the lack of a permanent solution leaves virtual care programs in limbo. PBM reforms move forward slowly: New policies aim to increase transparency and reduce incentives tied to drug list prices, though Pearl notes that meaningful change will depend on future implementation. Site-neutral payment gains attention: A provision requiring unique identifiers for outpatient services could pave the way for policies that eliminate higher reimbursement for hospital-owned facilities providing identical care. Measles outbreaks surge: Nearly a thousand cases have already been reported in 2026, with the overwhelming majority occurring among unvaccinated children. Trust in the CDC declines: Polling shows confidence in the agency has dropped significantly following changes to vaccine recommendations. Independent vaccine review groups emerge: Medical organizations and states are forming new committees to evaluate vaccine evidence as federal guidance becomes more contested. Early colon cancer deaths rise: The death of actor James Van Der Beek at age 48 highlights the growing incidence of colorectal cancer among younger adults and the importance of earlier screening. FDA confusion over a new flu vaccine: The agency initially declined to review Moderna's mRNA-based flu vaccine before reversing course and agreeing to evaluate it ahead of the next flu season. Younger Americans face worsening health trends: New claims data suggest chronic disease is appearing earlier among millennials and Gen Z, driven by lifestyle factors and reduced connection to primary care. Wearable data reveal health disparities: Apple Watch data show significant differences in resting heart rates across states, reflecting variations in lifestyle, access to care and public health conditions. As the episode concludes, Dr. Pearl warns that growing political conflict around vaccines and biomedical research risks undermining public trust in science. The consequences, he argues, could shape American medicine for decades to come. Tune in for more fact-based analysis and discussion of the biggest stories in healthcare. * * * Dr. Robert Pearl is the author of the new book “ChatGPT, MD: How AI-Empowered Patients & Doctors Can Take Back Control of American Medicine” about the impact of AI on the future of medicine. Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on Twitter and LinkedIn The post MTT #104: TrumpRx, rising measles cases & the politics of vaccine science appeared first on Fixing Healthcare.

Moderna, Abercrombie & Fitch, Eli Lilly, Nvidia... bajo la lupa de Juan Enrique Cadiñanos, CEO Global de Bullfy.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and regulatory evolutions shaping the landscape of medicine.One of the most significant recent developments involves Boehringer Ingelheim's drug Hernexeos, which has seen a rapid expansion in its use as a first-line treatment for non-small cell lung cancer (NSCLC). This expansion was made possible through the FDA's Commissioner's National Priority Voucher, an initiative designed to fast-track the approval of treatments addressing critical needs. This rapid progression highlights a commitment to accelerating access to crucial oncological treatments, emphasizing the role of accelerated regulatory pathways in swiftly delivering innovative therapies to patients who need them the most.In oncology, a combination therapy involving Padcev and Keytruda is showing promising results in improving overall survival rates for patients with muscle-invasive bladder cancer who are eligible for cisplatin. However, the continuously evolving landscape of treatment options for this cancer type means that further evaluation is necessary. This scenario highlights the ever-changing nature of oncology strategies and the ongoing need for clinical validation to determine the most effective treatment regimens.Switching gears to immunology, UCB's Bimzelx has reached a significant sales milestone, reflecting its growing influence in treating multiple indications. This success points to an expanding market for immunology therapeutics, as the industry remains focused on developing blockbuster treatments that can serve various conditions effectively.On the regulatory front, Moderna's combination influenza/COVID-19 vaccine has received a positive review from the European Medicines Agency's Committee for Medicinal Products for Human Use. This green light exemplifies the EU's dedication to thorough scientific evaluations. It contrasts with the FDA, which has exhibited hesitancy in this area, highlighting how varying regulatory approaches can affect drug availability in different regions.The field of HIV treatment is also seeing progress with GSK's ViiV division confirming the efficacy of its long-acting Cabenuva regimen for adolescents over a 96-week period. This long-acting regimen provides an alternative to daily oral therapies, potentially improving adherence and outcomes among younger populations—a crucial factor in managing chronic conditions effectively.Meanwhile, legal developments are stirring as the debate over "skinny labeling" for generic drugs reaches a pivotal point. The U.S. Supreme Court is being urged to overturn a ruling that endangers this pathway, highlighting the fine balance between fostering generic drug competition and protecting pharmaceutical innovation. In related legislative discussions, a Senate hearing focused on the FDA's rare disease review process has brought to light concerns about bureaucratic obstacles that may slow innovation. There is a call from stakeholders for more streamlined processes to ensure timely access to treatments for rare diseases—a sentiment echoed by many in the industry.The burgeoning field of CAR-T cell therapies continues to make waves, especially against solid tumors. Recent preclinical studies have shown potential efficacy in eradicating solid tumors in mice models. Despite these promising findings, significant regulatory challenges remain, and streamlining approval processes could accelerate their clinical application.In other significant news within the industry, Novartis has completed its acquisition of Avidity Biosciences for $12 billion, leading to the creation of Atrium Therapeutics. With a capitalization of $270 million, Atrium emerges with two promising preclinical candidates targeting cardiovascular conditions, signaling potential advSupport the show

Cinco clásicos de la música popular cubana nos permitirán recordar el debut discográfico del Quinteto de Música Moderna hacía 1960 gracias al empeño del productor Adolfo Semana a través de su etiqueta "Tropicana". Frank Emilio al piano, Papito Hernández en contrabajo, Tata Güines en las tumbadoras, Gustavo Tamayo en güiro y Guillermo Barreto en pailas y drums, indistintamente. "No te importe saber", "Nuestra canción","De ti enamorado ", "La gloria eres tú " y "Rico melao". Compositores: René Touzet, Cesar Portillo de la Luz, Julio Gutierrez, José Antonio Méndez y Jorge Mazón. Seguidamente volvemos a las antológicas emisiones de la CMQ ya reubicados sus estudios en el novedoso emplazamiento de 23 y M en el Vedado habanero. En marzo de 1948 el Conjunto "Matamoros" con Siro Rodríguez, Rafael Cueto, Miguel Matamoros y un juvenil Carlos Embale, formó parte de los llamados "Bailables Aniversario". Programas con los que el importante emporio radiofónico, por esas fechas, celebraba su fundación. El feeling eterno de Elena Burke. El álbum "Elena en primera persona" registrado en 1995 por el sello EGREM, resultó ser una de sus últimas entregas discográficas. Agradecemos el empeño de nuestro entrañable Jorge Rodríguez, notable productor, por materializar ese proyecto y preservar el arte inmenso de nuestra Señora Sentimiento. Otras dos voces esenciales de la música popular cubana despiden el programa: Miguelito Cuní con un septeto típico de sones bajo la batuta del tresero Niño Rivera y la trompeta de "Florecita" Velasco protagonizó en 1960 el álbum "Sones de ayer", formidable edición de la etiqueta Gema de los hermanos Álvarez Guedes con algo de la obra del compositor Bienvenido Julián Gutiérrez. Le sigue Graciela Pérez. En el Nueva York de comienzos de los años 40, como parte de la delantera vocal de los Afrocubans de su hermano Machito, esta cubanísima intérprete hizo historia.

El Dr. Patel es Jefe de Cardiología en Vitruvian Health y cardiólogo intervencionista y estructural certificado. Estudió medicina en la Facultad de Medicina de la Universidad Emory en Atlanta, Georgia, y completó su residencia en medicina interna en la Universidad de California en San Francisco, California. Obtuvo su Maestría en Administración de Empresas en la Facultad de Administración Kellogg de la Universidad Northwestern en Evanston, Illinois.También realizó su especialización en cardiología en la Facultad de Medicina Feinberg de la Universidad Northwestern en Chicago, Illinois, y posteriormente se formó en cardiología estructural e intervencionista en la Facultad de Medicina de la Universidad Emory en Atlanta, Georgia.https://vitruvianhealth.com/services/heart-vascular

This 'Media Buzz Meter' first aired on February 19th, 2026… Howie Kurtz on Former Prince Andrew being arrested on allegations of sharing UK trade secrets with Jeffrey Epstein, the partial government shutdown impacting FEMA's disaster recovery efforts, and the FDA's decision to review Moderna's application for an mRNA-based flu vaccine. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Netflix, Dell, Meta, Amazon, Moderna...bajo la lupa de Ricardo Tomás, asesor del fondo Multigestión Basalto USA.

In "Somebody to Lean On," Dr. Osterholm and Chris Dall discuss vaccine updates including the FDA's back-and-forth on the Moderna vaccine, leadership shake-ups at institutions like the CDC, and the current state of measles in the US. Dr. Osterholm will also bring you a respiratory virus update, including current vaccine guidance for flu, COVID and RSV. Op-Ed: The FDA refused to review a flu vaccine, contrary to evidence. Now the agency reversed itself (CIDRAP) The State of US Vaccine Policy (CIDRAP and Unbiased Science)Dentists still write millions of prescriptions a year for an antibiotic with life-threatening risks (CIDRAP)  Resources for vaccine and public health advocacy: Voices for Vaccines Families Fighting Flu Vaccinate Your Family Shot@Life Medical Reserve Corps Learn more about the Vaccine Integrity Project MORE EPISODES       SUPPORT THIS PODCAST   Music: "Beauty Flow" Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 4.0 License

We're marking Rare Disease Month 2026 by highlighting the powerful story of Shanthi Hegde, a young patient advocate working to transform how bleeding disorders are understood, treated, and supported. This work is fueled by her own arduous journey with two rare bleeding disorders and immune dysregulatory syndrome, and an extended diagnostic odyssey marked by dismissal, underdiagnosis, and structural bias. “I was told many times by many providers that these disorders are not common in Indians and that my bruises were there just because I'm brown.” Admirably, Shanthi pushed past this mistreatment, advocated for her medical needs, and devoted herself to tackling a range of issues confronting rare disease patients from mental health access to affordable drug pricing to research equity. In this remarkable Year of the Zebra conversation with host Lindsey Smith, you'll also learn about: Shanti's work with the Hemophilia Federation of America; How gaps extend beyond treatment to include insurance coverage, provider training, and substance use care; What clinicians can do to improve the work they do with rare disease patients. Join us for a conversation that connects patient voice to system change, and explores what real equity for rare disease communities will require. Mentioned in this episode:Hemophilia Federation of AmericaShanthi's LinkedIn Profile If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Announcements: SOTU @5:47 Follow-ups: FDA does a 180, decides it will review Moderna's mRNA vaccine @8:51 Fetterman at SOTU @9:40 Religious Nonsense: Tennessee bill would require public schools to teach the Bible @9:45 Earlier this week, another big Texas school district said “no, thanks” @11:24 Hegseth invited pastor to lead Pentagon prayer service @12:10 State of the Union update @14:23 PRRI released a new report on Christian Nationalism @15:55 News: Armed Man Is Fatally Shot at Mar-a-Lago @18:15 Trump Considers Targeted Strike Against Iran @22:22 Jared's take on the Men's Hockey team @26:19 Ambassador Mike Huckabee suggests Israel has God-given right to Middle East @26:47 Andy Win arrested @29:41 Peter Mandelson, Ex-Ambassador to the U.S. Arrest @33:41 Politics: DoW Christian Service Draws Complaints @35:37 Ohio mayor arrested on voyeurism charges @42:34 Health/Medicine/Science: NIH Director Jay Bhattacharya the new interim director of the CDC @48:56 Uproar in MAHA because glyphosate @49:37 Skeptical Inquirer Experts warn about NIH director @57:14 U.S. Creating a brand-new parallel WHO org @57:43 Final Stories: Flavor Flav invites USA women's hockey team to 'real celebration' @58:25

⚠️ Si quieres el episodio completo con todas las anécdotas y momentos extras, hazte Patreon aquí: https://www.patreon.com/losdanko ------------ ¡Damos un nuevo giro de tuerca al podcast OG de la podcasfera global! Tras el aluvión de mensajes que nos habéis enviado compartiendo vuestras (nefastas) experiencias en redes sociales y apps de ligoteo, hemos tenido que tomar medidas drásticas. Ante la avalancha de anécdotas de nuestras oyentes, incorporamos oficialmente a Lua Danko al equipo. Ella llega para ser la voz de la razón y el puente con las nuevas generaciones, intentando compensar el nivel de "pollaviejismo" y desfase de estos dos cuñados de confianza: El Pelos de Ripollet y Sam Danko, el del tranco. ¿Qué te vas a encontrar en este episodio? Técnicas de seducción "Vintage": ¿Funciona el pico-palismo insistente para enamorar a la más popular del pueblo o es acoso de manual? Analizamos anécdotas reales. Esquivando balas: Ghostings épicos que, más que un desplante, fueron una bendición divina para no acabar con un orco. Diccionario Gen Z: "Cringe", "Literal", el misterioso "6, 7..." y cómo estas expresiones están destruyendo el cerebro de Sam y El Pelos mientras Lúa trata de poner a nuestros héroes amateur al día. Y muchas sorpresas más que harán que te sientas menos solo en este mercado del amor tan roto. ---------------- EXCLUSIVO PARA PATREONS (Versión Extendida) Si te quedas con ganas de más, en la versión sin censura y en HD disponible en nuestro Patreon, El Pelos y Sam se ponen serios (o lo intentan) para debatir sobre MICHAEL, la nueva película biográfica del Rey del Pop. ¡Toda la Crema Dentro! HAZTE PATREON AQUÍ: https://www.patreon.com/losdanko, y accede a miles de horas de contenido extra mientras nos ayudas a que este circo siga en pie. --------------- Enlaces de interés: Web oficial: losdanko.com Comunidad Telegram: @mondodanko Publicidad: advoices.com/podcast/ivoox/1313

American officials say they believe China held a nuclear test in 2020, and President Trump reserves the right to do the same, as the New Start arms-control treaty with Russia hits its expiration date this month. Plus, the Food and Drug Administration summarily rejects a flu vaccine from Moderna, before changing course. Learn more about your ad choices. Visit megaphone.fm/adchoices

Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury's analysts assess what the deal does for the Foster City, Calif.-based biotech's pipeline.The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week's PhRMA Forum, which focused on China and the Trump administration's most favored nation (MFN) drug pricing policy, and on the lessons that can be drawn from FDA's about-face on the recent vaccine application from Moderna.View full story: https://www.biocentury.com/article/658516#BiotechMA #MultipleMyeloma #ctDNA #DrugPricingPolicy #FDA00:00 - Introduction02:34 - Gilead's Arcellx Buy11:14 - ctDNA Surrogate Endpoints21:59 - PhRMA Forum Takeaways29:19 - FDA Moderna U-turnTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

La politique antivaccins des Etats-Unis ne lui facilite pas la tâche. Depuis la fin de la pandémie, la biotech américaine Moderna perd de l'argent. Elle s'est peu renouvelée depuis qu'elle a vendu au monde entier son vaccin contre le Covid. Dans «La Story», le podcast d'actualité des «Echos», Clara Grouzis et Myriam Chauvot racontent les déboires de cette entreprise.« La Story » est un podcast des « Echos » présenté par Clara Grouzis. Cet épisode a été enregistré en février 2026. Rédaction en chef : Clémence Lemaistre. Invitée : Myriam Chauvot (journaliste aux Echos spécialiste de la santé). Réalisation : Willy Ganne. Chargée de production et d'édition : Clara Grouzis. Musique : Théo Boulenger. Identité graphique : Upian. Photo : AdobeStock. Sons : Arte, RMC, RTBF, Washington Post.Retrouvez l'essentiel de l'actualité économique grâce à notre offre d'abonnement Access : abonnement.lesechos.fr Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Gregory Zuckerman highlights Moderna's desperate struggle for funding and manufacturing equipment, which was finally resolved by a massive Wall Street investment during the pandemic's peak. 5

Gregory Zuckerman describes the climactic moment vaccine results arrived, with Pfizer and Moderna reporting high efficacy, while Novavax and AstraZeneca faced unique logistical and reputational challenges. 7

Why did Walmart fall on strong earnings? And how are Omnicom's big cost cuts boosting its stock? Plus, will a major FDA reversal change Moderna's fortunes? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them.Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Why did Walmart fall on strong earnings? And how are Omnicom's big cost cuts boosting its stock? Plus, will a major FDA reversal change Moderna's fortunes? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them.Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Food and Drug Administration will review Moderna's new flu vaccine after reversing course. Medicare Advantage growth in 2026 is trailing prior years. And Amazon is expanding same-day prescription delivery to nearly 5,000 cities nationwide. Those stories and more on today's episode of The Gist Healthcare Podcast. Hosted on Acast. See acast.com/privacy for more information.

TODAY ON THE ROBERT SCOTT BELL SHOW: Jonathan Emord, Pharma Attacks RFK Jr., FDA Moderna Reversal, MAHA Midterm Strategy, Voter ID, Hawaii's Emergency Power Grab, Ari Whitten, Red Light Therapy, Inflammation Reduction, Anhalonium Lewinii, and MORE! https://robertscottbell.com/jonathan-emord-pharma-funded-attacks-on-rfk-jr-fdas-moderna-reversal-maha-midterm-strategy-voter-id-hawaiis-emergency-power-grab-anhalonium-lewinii-and-more/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

The Trump administration appears to be gearing up for a substantial response to Iran, Washington State allegedly spends millions on gender surgeries for inmates, and whiplash hits Moderna as the FDA reverses its decision to not review the company's new flu vaccine. Get the facts first with Morning Wire.- - -Ep. 2640- - -Wake up with new Morning Wire merch: https://bit.ly/4lIubt3- - -Today's Sponsors:Hello Fresh - Go to https://HelloFresh.com/morningwire10fm to Get 10 free meals + a FREE Zwilling Knife (a $144.99 value) on your third box. Offer valid while supplies last.Vanta - Get started at https://Vanta.com/MORNINGWIRE- - -Privacy Policy: https://www.dailywire.com/privacymorning wire,morning wire podcast,the morning wire podcast,Georgia Howe,John Bickley,daily wire podcast,podcast,news podcast Learn more about your ad choices. Visit podcastchoices.com/adchoices

The twists and turns continue at the nation's health agency, where this week's announcements included notice that the Food and Drug Administration will review Moderna's new flu vaccine after all and that a handful of top agency officials are getting new jobs.Those developments and others can be traced to a White House looking to shake things up before the midterms — and win over voters on health care. Tami Luhby of CNN, Shefali Luthra of The 19th, and Lauren Weber of The Washington Post join KFF Health News' Mary Agnes Carey to discuss these stories and more. Visit our website for a transcript of this episode.Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too:  Mary Agnes Carey: Politico's “Why Congress Failed To Reach an Obamacare Deal,” by Robert King and Simon J. Levien. Lauren Weber: NiemanLab's “The Atlantic's Elizabeth Bruenig on Her ‘Hypothetical,' Heavily Reported Measles Essay,” by Laura Hazard Owen. Tami Luhby: The City's “NewYork-Presbyterian Nurses Reject Contract by Overwhelming Margin,” by Claudia Irizarry Aponte and Ben Fractenberg. Shefali Luthra: NPR's “Minneapolis Doctors Warn of Lasting Medical Effects, Even After ICE Agents Leave,” by Jasmine Garsd. 

Howie Kurtz on Former Prince Andrew being arrested on allegations of sharing UK trade secrets with Jeffrey Epstein, the partial government shutdown impacting FEMA's disaster recovery efforts, and the FDA's decision to review Moderna's application for an mRNA-based flu vaccine. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This week on The Health Advocates, we unpack a series of developments that signal a pivotal moment in U.S. health policy. The FDA has refused to review Moderna’s new mRNA-based flu vaccine, raising questions about regulatory standards and the future of vaccine innovation. At the same time, the Trump administration has launched TrumpRx, a new prescription drug discount platform that promises savings but faces scrutiny over its scope and real-world impact.We also examine new polling showing declining confidence in flu, COVID-19, and MMR vaccines, and the growing legal battle over changes to the federal childhood vaccine schedule. With public trust, regulatory rigor, and patient access all in play, this episode breaks down what these headlines mean for patients — and why clarity and credible science matter more than ever. Contact Our HostSteven Newmark, Chief of Policy at GHLF: snewmark@ghlf.orgA podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF.We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.orgListen to all episodes of The Health Advocates on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

Few issues have tested public trust in medicine as deeply as vaccines, and few individuals have influenced that dialogue more than Dr. Paul Offit, director of the Vaccine Education Center at the Children's Hospital of Philadelphia and a longtime member of the FDA's Vaccine Advisory Committee. In this timely and candid interview with Raise the Line host Lindsey Smith, Dr. Offit points to this year's severe flu season and a resurgence of measles as alarming proof points of how a changing federal perspective on vaccine policy is having a real impact on public health. “You'd like to think you can educate about the importance of vaccines, but I fear at this point the viruses themselves are doing the educating.” In this wide ranging discussion, Dr. Offit also addresses: The rigorous and painstaking process of developing vaccines, based on his experience co-inventing the rotavirus vaccine. Shifting levels of public trust in scientific organizations. Promising innovations in vaccine development. Don't miss this deeply-informed perspective on the interplay of science, policy, and public education, and his encouraging message to young clinicians about managing the current challenges in public health.  Mentioned in this episode: Vaccine Education Center at Children's Hospital of PhiladelphiaPerelman School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

The Food and Drug Administration agreed to begin a review of biotech company Moderna's application to make a new seasonal flu shot available. The decision comes after the FDA initially refused to review the company's application. It's a back and forth that reveals increased turmoil within the agency. WSJ's Liz Essley Whyte takes us inside the FDA's unexpected reversals and explores what's next for the mRNA flu vaccine. Jessica Mendoza hosts.  Further Listening: - The FDA Commissioner on Vaccines and Public Trust - Breakfast Battle: The Cereal Industry vs MAHA Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Something strange is happening in the culture and the headlines are only telling part of the story. From rising violence tied to gender confusion to major pharmaceutical companies losing ground and questions about what is really in our food supply, the pieces are starting to connect. I walk through why these issues are surfacing at the same time and what it reveals about the deeper battle shaping our future. By the end you will see why discernment matters more right now than outrage and how to stand steady while the narrative keeps shifting.   Podcast Episode 2034: Gender Confusion Violence Pattern, Moderna Stock DROPS + Our Food is POISON?! | don't miss this! Listen to more episodes of the Lance Wallnau Show at lancewallnau.com/podcast

In our news wrap Wednesday, the National Institutes of Health Director Dr. Jay Bhattacharya will serve as acting head of the CDC, the FDA reversed its decision to consider whether to approve a new mRNA flu shot from Moderna and billionaire Les Wexner told lawmakers he was "duped by a world-class con-man" as he faced questions about his association with Jeffrey Epstein. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Rescue teams are searching for missing skiers caught in an avalanche near Lake Tahoe amidst a winter storm. After a setback, authorities continue to canvass neighborhoods for clues in the disappearance of Nancy Guthrie. We'll tell you about another set of deadly US strikes on suspected drug-smuggling vessels. The FDA has reversed course and agreed to review a major drugmaker's flu vaccine. Plus, a software giant says it's on track to invest billions to help low incomes countries gain access to AI. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Plus: U.S. industrial production rose in January. What Berkshire Hathaway bought and sold during Warren Buffett's last quarter as CEO. And Mikaela Shiffrin wins the gold in the women's slalom. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

──────────────────────────────────── 00:00:51:15 — Directed Energy Weapons Move From Theory to BattlefieldAutonomous killer systems and microwave weapons are described as transitioning from speculation into active military doctrine. ──────────────────────────────────── 00:07:44:24 — Intelligence Agencies Downplayed Directed Energy CapabilitiesInternal awareness of microwave weapon effects is contrasted with public minimization of their existence. ──────────────────────────────────── 00:14:59:19 — Hypersonic Missiles Undermine “Golden Dome” DefenseAdvanced missile systems are cited as rendering proposed U.S. missile shields technologically and financially unrealistic. ──────────────────────────────────── 00:21:12:01 — Federal Agents Escalate Use of Crowd-Control WeaponsTear gas, flash bangs, and rubber bullets are reportedly deployed broadly against protesters and bystanders. ──────────────────────────────────── 00:29:13:09 — Body Cam Footage Captures Aggressive Use-of-Force DirectiveA supervisor's recorded comments raise concerns about normalization of escalatory force tactics. ──────────────────────────────────── 00:35:48:25 — Federal Immunity Shields Officers From AccountabilityBroad immunity claims collide with court findings noting repeated excessive-force violations. ──────────────────────────────────── 01:04:52:09 — FDA Blocks New mRNA Flu ShotRegulators halt advancement of a Moderna flu vaccine, breaking with expectations of streamlined approval. ──────────────────────────────────── 01:18:50:21 — Vaccines Framed as National Security InfrastructureGlobal health leaders argue vaccine production should operate as centralized state security architecture. ──────────────────────────────────── 01:23:54:27 — Pandemic Policies Normalize Permanent Emergency PowersMandates, liability shields, and censorship are portrayed as embedded tools of governance beyond crisis conditions. ──────────────────────────────────── 01:24:17:13 — Legislative Push to End Vaccine Manufacturer ImmunityNew legislation challenges longstanding liability protections for pharmaceutical companies. ──────────────────────────────────── 01:43:14:10 — Third-Term Discussion Challenges Constitutional LimitsPublic talk of bypassing the 22nd Amendment is framed as normalization of executive permanence. ──────────────────────────────────── 01:55:48:12 — Convicted Elites Rebrand Through Alternative MediaDisgraced figures leverage online platforms to rebuild public narratives and pressure for clemency. ──────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

The U.S. Food and Drug Administration announced recently that it will not review Moderna's mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and outside the industry concerned about the Trump administration's approach to vaccine development and recommendations. Amna Nawaz discussed more with Michael Osterholm. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

──────────────────────────────────── 00:00:51:15 — Directed Energy Weapons Move From Theory to BattlefieldAutonomous killer systems and microwave weapons are described as transitioning from speculation into active military doctrine. ──────────────────────────────────── 00:07:44:24 — Intelligence Agencies Downplayed Directed Energy CapabilitiesInternal awareness of microwave weapon effects is contrasted with public minimization of their existence. ──────────────────────────────────── 00:14:59:19 — Hypersonic Missiles Undermine “Golden Dome” DefenseAdvanced missile systems are cited as rendering proposed U.S. missile shields technologically and financially unrealistic. ──────────────────────────────────── 00:21:12:01 — Federal Agents Escalate Use of Crowd-Control WeaponsTear gas, flash bangs, and rubber bullets are reportedly deployed broadly against protesters and bystanders. ──────────────────────────────────── 00:29:13:09 — Body Cam Footage Captures Aggressive Use-of-Force DirectiveA supervisor's recorded comments raise concerns about normalization of escalatory force tactics. ──────────────────────────────────── 00:35:48:25 — Federal Immunity Shields Officers From AccountabilityBroad immunity claims collide with court findings noting repeated excessive-force violations. ──────────────────────────────────── 01:04:52:09 — FDA Blocks New mRNA Flu ShotRegulators halt advancement of a Moderna flu vaccine, breaking with expectations of streamlined approval. ──────────────────────────────────── 01:18:50:21 — Vaccines Framed as National Security InfrastructureGlobal health leaders argue vaccine production should operate as centralized state security architecture. ──────────────────────────────────── 01:23:54:27 — Pandemic Policies Normalize Permanent Emergency PowersMandates, liability shields, and censorship are portrayed as embedded tools of governance beyond crisis conditions. ──────────────────────────────────── 01:24:17:13 — Legislative Push to End Vaccine Manufacturer ImmunityNew legislation challenges longstanding liability protections for pharmaceutical companies. ──────────────────────────────────── 01:43:14:10 — Third-Term Discussion Challenges Constitutional LimitsPublic talk of bypassing the 22nd Amendment is framed as normalization of executive permanence. ──────────────────────────────────── 01:55:48:12 — Convicted Elites Rebrand Through Alternative MediaDisgraced figures leverage online platforms to rebuild public narratives and pressure for clemency. ──────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

We get the latest from the Munich Security Conference, where U.S. Secretary of State Marco Rubio delivered a speech before European leaders. We also look at the reasons behind why the FDA rejected Moderna's new flu vaccine and how that decision could shape future clinical trials. Plus, we'll look at the what happened with U.S Olympic figure skater Illia Malinin, dubbed the "Quad God," on the ice yesterday. Tipped to win the gold, Malinin didn't end up even medaling. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

It looked like Shopify's stock was headed for a great day when it reported earnings, only for the stock to give up all its gains and then some when management started talking on the conference call. The gang discusses why management's comments had such a profound effect on the stock. Plus, a look at Moderna after the recent FDA approval and stocks on our radar Tyler Crowe, Matt Frankel, and Jon Quast discuss: - The market's sharp reaction to Shopify's earnings - e-commerce in the era of agentic commerce - The FDA's refusal to review Moderna's new flu vaccine - Stocks on our radar Companies discussed: SHOP, AMZN, GOOG, PINS, WMT, MRNA, TREX, CROX, SAFRY Host: Tyler Crowe Guests: Matt Frankel, Jon Quast Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

On the DSR Daily for Wednesday, we discuss the Congressional hearing on immigration oversight, the FDA rejecting a Moderna flu vaccine, growing calls for the resignation of Howard Lutnick, and more.  Learn more about your ad choices. Visit megaphone.fm/adchoices